Malignant Melanoma | Current Treatment: Physician Insights | US | 2017
The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune checkpoint inhibitors (ICIs) and BRAF/MEK-targeted therapies have changed the treatment landscape dramatically. Combination therapies are playing an increasingly greater role in the unresectable recurrent or metastatic setting, including regimens such as Novartis’s Tafinlar plus Mekinist (2014), Roche/Genentech’s Zelboraf plus Cotellic (2015), and Bristol-Myers Squibb’s Opdivo plus Yervoy (2015). Consequently, optimizing sequencing decisions is a key focus for prescribing oncologists, irrespective of patients’ BRAF mutation status.
Related Market Assessment Reports
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
